Biotech firm Arvinas' Q3 net loss narrows

Arvinas

05/11/2025 12:19

Overview

Arvinas Q3 revenue drops significantly year-over-year, impacted by completed Novartis agreements

Net loss for Q3 narrows compared to last year

R&D expenses decrease due to lower external and personnel costs

Outlook

Arvinas plans to initiate a Phase 1b trial for ARV-102 in PSP patients in 1H 2026

Company expects to present ARV-393 data at a medical congress in 2026

Arvinas plans to continue ARV-806 Phase 1 trial enrollment in KRAS G12D tumors

Result Drivers

R&D EXPENSES - The decrease in R&D expenses of $22.2 million for the quarter was primarily due to a decrease in external expenses of $7.4 million and a decrease in compensation and related personnel expenses of $14.2 million

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$41.90 mln
Q3 Net Income
-$35.10 mln
Q3 Operating Expenses
$85.70 mln
Q3 Operating income
-$43.80 mln
Q3 Pretax Profit
-$34.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arvinas Inc is $13.00, about 26.6% above its November 4 closing price of $9.54

Press Release: ID:nGNX54TB1Z

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)